IGC Pharma added Dominion Medical Associates, a Richmond, Virginia‑based clinical research site, to its Phase 2 CALMA trial that evaluates IGC‑AD1 for agitation in Alzheimer’s disease.
The new site will operate under Lightship’s hybrid model, which blends in‑clinic visits with remote and in‑home assessments. The hybrid approach is designed to increase patient access, improve retention, and broaden geographic reach, especially in underserved and rural communities.
Adding Dominion Medical Associates is expected to lift enrollment velocity and help IGC Pharma reach its target of delivering Phase 2 results by mid‑2026. The trial was 65 % enrolled as of December 2025, and the additional site is projected to accelerate enrollment by an estimated 10–15 % over the next six months.
IGC Pharma’s financial position remains tight, with a net cash balance of roughly $968,000 and negative free cash flow. The expansion is part of the company’s “burn‑the‑boats” strategy, which prioritizes resources for IGC‑AD1 and signals management’s confidence in the trial’s potential to generate a positive readout that could unlock future funding.
CEO Ram Mukunda said the addition of Dominion Medical Associates “represents a meaningful step forward in expanding access to our CALMA trial. The hybrid model aligns with our strategy to reach patients in underserved and rural communities while maintaining high‑quality clinical oversight and data integrity.”
The move reflects a broader industry shift toward decentralized clinical trials, which can reduce costs and improve data quality. If enrollment targets are met, the accelerated timeline could position IGC Pharma to secure additional capital or a partnership before the company’s limited cash runway expires.
While the site expansion is a positive operational development, investors will closely monitor enrollment progress and the company’s ability to manage cash burn. Successful execution could validate IGC Pharma’s “burn‑the‑boats” approach and enhance the likelihood of a mid‑2026 readout that supports future growth.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.